Related Experiment Video

Updated: Nov 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.6K

Risk of subsequent atrial fibrillation in patients with myasthenia gravis: A population-based cohort study

Yaw-Tzeng Liou1, James Cheng-Chung Wei2,3,4, Kai-Chieh Hu5

  • 1Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung.

Medicine
|May 20, 2021
PubMed

Insights

This study found no increased risk of atrial fibrillation (AF) in patients with myasthenia gravis (MG). The research in a Taiwanese population indicates MG is not a risk factor for developing AF.

Area of Science:

  • Cardiology
  • Neurology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Atrial fibrillation (AF) is a common cardiac arrhythmia with significant health implications.

Purpose of the Study:

  • To investigate the association between myasthenia gravis (MG) and the risk of developing atrial fibrillation (AF).
  • To analyze this association within an Asian population, specifically a Taiwanese cohort.

Main Methods:

  • A cohort study design was employed, comparing 5528 patients with MG to 5528 matched individuals without MG.
  • Data was sourced from a hospitalization claim dataset.
  • Cox proportional hazard models were utilized to estimate hazard ratios and confidence intervals, adjusting for covariates.

Main Results:

  • The adjusted hazard ratio for AF in the MG group compared to the non-MG group was 1.03 (95% CI, 0.76-1.38).
  • Stratified analyses by age, gender, and comorbidities, as well as different follow-up periods, revealed no increased risk of AF in patients with MG.

Conclusions:

  • Myasthenia gravis is not associated with an increased risk of atrial fibrillation in the Taiwanese population.
  • The findings suggest that MG does not appear to be a predictive factor for AF development.

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.0K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
44
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
77
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
62